Navigation Links
Reportlinker Adds Pharmaceutical Contract Manufacturing: Industry and Market Prospects 2010-2025

NEW YORK, Oct. 7 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Pharmaceutical Contract Manufacturing: Industry and Market Prospects 2010-2025

Report Details -- opportunities and challenges for the sector and its customersHow will the contract manufacturing sector adapt to the needs of pharma from 2010 onwards? Our new report will show you trends and prospects there. How will the sector and its customers face challenges and opportunities? We show commercial benefits for the pharma contract manufacturing sector and its customers, including revenue trends for 2010-2025. You can have that report today, staying ahead.

Contract manufacturing is an expanding sector, with rising prominence. Which of its segments will grow fastest from 2010? What are the commercial trends to watch? How will companies perform? You will discover how the worldwide market for pharmaceutical contract manufacturing will perform from 2010 to 2025.

Contract manufacturing services in emerging countries are increasingly prominent. That trend is accelerated by rising numbers of contract manufacturing organisations (CMOs) in those countries and the globalisation of pharma manufacturing. Our report shows how you can benefit, saving time and aiding your work.

This report covers all the important considerations for those within the contract pharma manufacturing industry. We also provide an understanding of the sector for companies that are considering the outsourcing of production. This sector will expand and extend its capabilities from 2010 onwards.

Pharma contract manufacturing has been changing, a trend that will continue. Cost-efficiencies and rapid time-to-market are crucial. There is rising competition and demand. Increasingly specialised requirements will appear – especially for biological products. Demand for APIs will particularly influence contract manufacturing from 2010 onwards. Our report shows you its technological and commercial potential, revealing opportunities and challenges.

Analysis of the pharma contract manufacturing sector to meet your needsOur new report examines the contract manufacturing sector critically. We harness primary and secondary research to meet your needs. We provide revenue forecasts, market share analyses and other data. You will discover market strengths, weaknesses, opportunities and threats. We include many tables, figures and expert interviews, as shown in the contents listing with this message.

Why you should buy Pharmaceutical Contract Manufacturing: Industry and Market Prospects 2010-2025Our report gives you the following benefits in particular:

  • You will receive hard data for the contract manufacturing sector – and much more – including our revenue predictions from 2010 to 2025
  • You will receive analyses for the overall market and its main components, helping you to stay ahead
  • You will find out potential revenues in leading national markets (US, Japan, Germany, France, UK, Italy, Spain, India, China) from 2010 to 2025
  • You will discover how the pharmaceutical contract manufacturing sector will change and adapt from 2010 to 2025
  • You will find out how the sector can deliver improved services for APIs, finished dosage forms and other requirements
  • You will discover opportunities for established companies and new market entrants from 2010 to 2025, as well as their customers
  • You will discover the drivers, restraints, competition and opportunities influencing the sector
  • You will discover expert views from our survey, including full interview transcripts
  • You will find out where contract manufacturing is heading – technologically and commercially – from 2010 onwards.

  • Our study gives you answers and trends, saving you time and aiding your decisions.You can have this report todayOur new report can benefit everybody interested in pharmaceutical manufacturing. We forecast commercial potential, discovering trends. Do you want to harness those opportunities? Please let us know how we can help. You can stay ahead by ordering our report now.

    Table of Contents 1. Executive Summary

    1.1 Contract Pharma Manufacturing 2010-2025

    1.2 Aims, Scope and Format of the Report

    1.3 Research & Analysis Methods

    2. Introduction to Pharma Outsourcing of Manufacturing

    2.1 Contract Pharma Described

    2.1.1 Evolving Nature of Contract Research Organisations (CROs) and Contract Manufacturing Organisations (CMOs)

    2.2 Contract Development and Manufacturing Organisations (CDMO)

    2.3 Why Are Pharma Companies Interested in Contract Pharma?

    2.3.1 Small/Mid-sized Pharma and Biotech Have a Flexible Attitude to Outsourcing

    2.3.2 Lack of Capacity is Still a Major Reason to Outsource

    2.3.3 Tactical vs. Strategic Use of Outsourcing

    2.4 The Changing Nature of the Pharmaceutical Market is Affecting the CRM Market

    2.4.1 The Rise of Generics

    2.4.2 Pipelines are Becoming Expensive

    2.4.3 The Decline of the Traditional Blockbuster

    2.5 Biopharmaceutical Drug Discovery and Development by Contract Pharma Companies will Continue to Increase

    2.6 Disadvantages of Outsourcing in the Pharmaceutical Industry Can be Overcome

    3. Regulatory Aspects of Pharma Outsourcing for Manufacturing

    3.1 Legal Liabilities and Regulatory Considerations in Outsourced Manufacturing

    3.2 Summary of GMP Requirements

    3.3 Compliance with FDA Provisions is Vital

    3.4 EU Regulations and the Qualified Person Role

    3.5 Q7A Guidance for Active Pharmaceutical Ingredient (API) and Excipient Production

    3.6 Harmonisation of GMP Standards

    3.7 EU API Makers for Good Manufacturing Practices Inspections

    3.8 Enforcing cGMP Compliance for APIs in EU

    3.9 EU Requirements for Outsourcing Services

    3.10 Good Manufacturing Practice (GMP) Compliance

    3.11 API Requirements Challenge Outsourcing Services from China

    3.12 Summary: Globalisation Benefits Pharma Harmonisation

    4. The Outsourcing Decision

    4.1 Reasons to Outsource

    4.1.1 Outsourcing as a Tactical Decision

    4.1.2 Outsourcing as a Strategic Decision

    4.2 Cost-Benefit Analysis of Outsourcing

    4.3 Risks Associated with Outsourcing Incur Hidden Costs

    4.3.1 Errors and Delays Can Cost Millions

    4.3.2 Regulatory Compliance Must be Assured

    4.3.3 IP and Other Sensitive Data May be at Risk

    4.3.4 Management of Outsourcing Requires Continued Monitoring

    4.4 Technology Transfer Considerations

    4.5 The Virtual Company

    4.5.1 'Virtuality' Helps Control Rising Costs

    4.5.2 Strong Project and Operations Management is Vital

    4.5.3 The Challenges of Virtual Companies are Relevant Across the Industry

    4.6 Key Requirements for Successful Outsourcing

    4.6.1 Trust and Accountability

    4.7 Summary: Planning the Guiding Principle for Outsourcing

    5. Pharma Contract Manufacturing Industry and Market 2010-2025

    5.1 The World Contract Manufacturing Market in 2010

    5.2 Growing Market for Contract Manufacturing Services

    5.2.1 Revenue Forecast for Total Pharma Contract Manufacturing Market, 2010-2016

    5.2.2 Revenue Forecast for Total Pharma Contract Manufacturing Market, 2017-2025

    5.3 Breakdown of the Pharma Contract Manufacturing Market

    5.3.1 Revenue Forecast for API Market, 2010-2016

    5.3.2 Revenue Forecast for API Market, 2017-2025

    5.3.3 Revenue Forecast for Dosage Forms Market, 2010-2016

    5.3.4 Revenue Forecast for Dosage Forms Market, 2017-2025

    5.4 Leading National Markets for Pharma Contract Manufacturing, 2010-2025

    5.4.1 The US Pharma Contract Manufacturing Market, 2010-2025

    5.4.2 The Japanese Pharma Contract Manufacturing Market, 2010-2025

    5.4.3 The Leading European Pharma Contract Manufacturing Markets, 2010-2025

    5.4.4 Emerging Pharma Contract Manufacturing Markets

    5.4.5 The Indian Pharma Contract Manufacturing Market, 2010-2025

    5.4.6 The Chinese Pharma Contract Manufacturing Market, 2010-2025

    5.5 Summary of the Chapter

    6. Contract Manufacturing Sector to Provide Marked Benefits to Clients

    6.1 Reasons for Outsourcing

    6.2 Commercial Drivers of Outsourcing

    6.3 Commercial Restraints for Outsourcing

    6.4 API Manufacturers Closely Linked with Innovative Pharmaceutical Developers

    6.5 Various Outsourcing Partners

    6.6 Selecting an Appropriate CMO

    6.7 Management of the Supply Chain for Cost-Efficient Contract Manufacturing

    6.8 Mergers and Acquisitions for Pharmaceutical Manufacturing

    6.8.1 Alliances with CMOs – a Growing Trend in the US

    6.8.2 Patheon Forms Alliance with India's Kemwell

    6.9 Interview with Manish Badonia, Cadila

    6.9.1 Contract Manufacturing Outsourcing to Asia will Grow due to Cost Competitiveness

    6.9.2 Alliance Formation for Moving up the Value Chain

    6.9.3 Quality Control for Contract Pharma to Improve Further

    6.10 Contract Pharma for Biotech Products

    6.10.1 Failure in Early Efforts in Contract Biologic Manufacturing

    6.10.2 Cost Benefits of Outsourced Manufacturing in Biotech Sector

    6.10.3 The Future of Pharma Biotech Outsourcing

    6.10.4 Custom Peptides are an Opportunity for APIs to Move up the Value Chain

    6.10.5 One More Step for Outsourcing Contract Pharma Manufacturing to Asia

    6.11 Western Companies Can Compete by Moving into Speciality API Manufacturing

    6.12 Contract Pharma for Improved Process Tools

    6.13 Chinese API Export Growing Rapidly

    6.14 Outsourcing to Low-Cost Geographic Areas

    6.15 Low Cost Services in India and China Drive Prices Down

    6.16 Main Tendencies in Current Asian IP Law

    6.17 Patent Protection Status in Indian Pharmaceutical Industry

    6.18 Recommendation for Improvement of China's Intellectual Property Rights

    6.19 Interview with Dr Zhang Zhicheng, National Intellectual Property (IP) Strategy Formulation Office, SIPO, China

    6.19.1 International Framework: IP Protection for Contract Manufacturing

    6.19.2 IP Holders Get the Profits

    6.19.3 Changing IP Situation in the Developing Countries

    6.19.4 Innovation-Oriented Industry Development in China

    7. The Pharma Contract Manufacturing Sector in India

    7.1 Contract Manufacturing in India

    7.2 Drivers for Contract Manufacturing Outsourcing to India

    7.3 Contract Manufacturing and Role of Indian Companies

    7.3.1 Outsourcing for Generics

    7.3.2 Sourcing Generics from Non-Competitors

    7.3.3 Divis Laboratories' Business Model

    7.3.4 Granules India in Production of Generic Prescription Medicines and OTCs

    7.3.5 Matrix Acquired by PharmaLinkFHI/Novella, a Global CRO

    7.3.6 Neuland Focused on Anti-Bacterials

    7.3.7 Natco Chose Chronic Diseases

    7.4 Enforcing cGMP Compliance for APIs in EU

    7.5 Expansion of Indian Biotechnology Sector

    7.6 Interview with Dr Jagdish N Sheth, Business School, Emory University

    7.6.1 India's Key Strength

    7.6.2 India's Edge over China in Pharmaceutical Business

    7.6.3 Need for Routine Inspection of Outsourcing Sites

    7.6.4 Need for Creation of Economic Zone for Pharmaceutical Industry

    7.6.5 India as an Emerging Market

    7.6.6 Vertical Integration Recommended for India's Companies

    7.6.7 India's Emergence as a Major Pharmaceutical Market

    8. Contract Pharma for Specialised Areas

    8.1 Value-Added Services and Contract Pharma

    8.2 One-Stop Shop (CRO and CMO)?

    8.3 Interview with Manish Badonia, Cadila

    8.3.1 One-Stop Shop: CROs and CMOs

    8.3.2 Value-Added Services in Global Settings

    8.4 Interview with Wesley Wheeler, Patheon

    8.4.1 Outsourcing for Analytical Testing Services

    8.5 CMOs Venture into Development and Product Extensions

    8.6 The Use of CROs in Drug Discovery and Development is Increasing in Pharma Industry

    8.6.1 Contract Research for Drug Discovery at Suven Life Sciences

    8.7 Interview with Dr Debra Sponholtz, Chembiotek

    8.7.1 CROs Offer a Full Range of Services

    8.8 Outsourcing Electronic Data Management

    8.9 Outsourcing of Data Management in India

    8.9.1 GlaxoSmithKline to Outsource Data Management

    8.9.2 Wyeth (Pfizer): Outsourced Data Management

    8.10 Planning Required for Regulatory Affairs Outsourcing

    8.11 Outsourcing Bioequivalence Studies for Generic Drugs

    8.12 Requesting a Waiver from a Bioequivalence Trial

    8.13 Bioequivalence Studies for New Drug Applications

    8.14 Interview with Helmut Schutz, BEBAC

    8.14.1 When in Vivo Bioequivalent Studies are Waived for ANDA

    8.14.2 Success of Outsourcing Dissolution Testing/ Bioequivalence Studies

    8.14.3 Success of Off-Shoring in Vivo Bioequivalence Studies to India

    8.15 Interview with Dr Daniel Abran, Sandoz

    8.15.1 Waivers of in Vivo BE Studies (Biowaivers) for Abbreviated New Drug Applications

    8.15.2 Comparative Clinical Trial Requirement for ANDA

    8.16 Interview with Manish Badonia, Cadila

    8.16.1 Prospects for Outsourcing Bioequivalence Studies

    8.17 Outsourced Biostorage Becomes a Strategic Consideration

    8.18 Contract Pharma for Lyophilisation

    8.19 Contract Packaging Services

    8.19.1 Contract Packaging is Not Just Boxes and Packs

    8.19.2 Advantages Offered by Contract Packaging Organisations

    9. Conclusions from this Study

    9.1 Growth Rates will Vary According to Sector

    9.2 Contract Pharma Manufacturing Encompasses Requirements in Biotechnology

    9.3 Outsourcing for Value-Added Services

    9.4 Concluding Remarks

    List of Tables

    Table 2.1 Top 10 Pharma Biotech Products, 2009

    Table 2.2 Top 10 Biotech Companies: Revenues and Market Shares, 2009

    Table 5.1 Pharmaceutical Contract Manufacturing: World Revenue Forecast, 2010-2016

    Table 5.2 Pharmaceutical Contract Manufacturing: World Revenue Forecast, 2017-2025 Table 5.3 API Market: World Revenue Forecast, 2010-2016

    Table 5.4 API Market: World Revenue Forecast, 2017-2025

    Table 5.5 Finished Dosage Forms Market: World Revenue Forecast, 2010-2016

    Table 5.6 Finished Dosage Forms Market: World Revenue Forecast, 2017-2025

    Table 5.7 Pharma Contract Manufacturing Market: World Revenue Forecasts by Class, 2010-2016

    Table 5.8 Pharma Contract Manufacturing Market: World Revenue Forecasts by Class, 2017-2025

    Table 5.9 Pharma Contract Manufacturing (CM) National Market Forecasts, 2010-2015, 2020 & 2025

    Table 6.1 Alliances for APIs in India, 2010

    Table 6.2 Relationship Build-Up for Contract Manufacturing in India, 2010

    Table 6.3 SWOT Analysis for Contract Manufacturing Services from Developing Countries, 2010

    Table 6.4 Top US DMF Holders in India and China, 2007-2008

    Table 7.1 FDA-Approved Manufacturing Sites in India, 2010

    Table 9.1 Pharma Contract Manufacturing Market: World Revenue Forecast, 2010, 2012, 2015, 2018, 2020 & 2025

    List of Figures

    Figure 2.1 Examples of Contract Services During the Pharma Product Lifecycle, 2010

    Figure 2.2 The Role of Contract Pharma Organisations in Drug Development, 2010

    Figure 2.3 Comparison of R&D Costs and the Number of Approved NMEs, 2010

    Figure 5.1 Pharmaceutical Contract Manufacturing: World Revenue Forecast, 2010-2016

    Figure 5.2 Pharmaceutical Contract Manufacturing: World Revenue Forecast, 2017-2025

    Figure 5.3 API Market: World Revenue Forecast, 2010-2016

    Figure 5.4 API Market: World Revenue Forecast, 2017-2025

    Figure 5.5 Finished Dosage Forms Market: World Revenue Forecast, 2010-2016

    Figure 5.6 Finished Dosage Forms Market: World Revenue Forecast, 2017-2025

    Figure 5.7 Pharma Contract Manufacturing Market: World Revenue Forecasts by Class, 2010-2025

    Figure 5.8 US Pharma CM Market: Revenue Forecast, 2010-2025

    Figure 5.9 Other Leading Pharma CM National Markets: Revenue Forecasts, 2010-2025

    Figure 5.10 Pharma CM Revenue Shares in Leading National Markets, 2010

    Figure 5.11 Pharma CM Revenue Shares in Leading National Markets, 2015

    Figure 5.12 Pharma CM Revenue Shares in Leading National Markets, 2020

    Figure 5.13 Pharma CM Revenue Shares in Leading National Markets, 2025

    Figure 6.1 Top Ten Biotech Drugs: World Sales, 2009

    Figure 7.1 Path up the Value Chain for Indian Pharma Companies, 2010

    Figure 9.1 Pharma Contract Manufacturing Market: Revenue Trends, Overall and by Class, 2009-2025

    Companies Listed

    Abbott Laboratories


    Actelion Pharmaceuticals

    Aditya Dispomed Products

    Advanced Biotech Products

    Advanced Medical Optics

    Advanced Micronic Devices

    Advantage Dental Laboratories

    Alps International


    American Ortho-Tech


    Anaesthetics India



    Anhui BBCA Biochemical

    Apothecaries Sundries Manufacturing Company

    Appasamy Associates

    Appasamy Ocular Devices

    Ashva Technologies

    Aurobindo Pharma




    Baxter International

    BEBAC – Consultancy Services for Bioequivalence and Bioavailability Studies

    Bharat Enterprises

    Bilink International,

    Biogen Idec

    Biogenex Life Sciences

    Biotech Vision Care

    Bristol-Myers Squibb

    Cadila Pharmaceuticals

    Carbogen Amcis

    Catalent Pharma Solutions




    Cephas Medical

    Ceradyne India Ceramics


    Chifeng Arker Pharmaceutical Technology

    Chinese State Food and Drug Administration (SFDA)

    Chongqing Carelife Pharmaceutical

    Chongqing Daxin Pharmaceutical


    Consultancy Services for Bioequivalence and Bioavailability Studies (BEBAC, Austria)



    Cyber Approach

    Dabur India

    Dahlgren India

    Damon Biotech

    Degania Medical Devices

    Dishman Group

    Divis Laboratories

    Dr. Reddy's Laboratories

    Dr. Sabharwal's Manufacturing Labs

    Dr. Sabharwal's Medicals

    Dr. Sabharwal's Wound Care

    Eastern Medikit Limited

    Eclipsys India

    Eli Lilly

    Emory University

    Encube Ethicals

    Enkay (India) Rubber Co.

    Epsilon Eye Care

    eReady Monitors

    Essilor Manufacturing

    European Medicines Agency (EMA/EMEA)

    Flexit Laboratories

    Food and Drug Administration (FDA, US)

    G K B Rx Lens

    Ganko Opticians

    GE Medical Systems (India)

    General Surgical Company



    Genzyme Corp

    George Philips Medical Engineering

    Gilead Sciences

    Gillette Diversified Operations

    Gkb Ophthalmics

    Gkb Rx Lens


    Glenmark Pharmaceuticals

    Gpc Medical

    Grandeur Exports

    Granules India

    Gst Corporation

    H.P. Industries

    Harmony Plastics

    Hero Exports

    Hetero Drugs

    Himedia Laboratories

    Hindustan Syringes & Medical Devices

    Hll Lifecare

    Hollister Medical India

    Hollister-Stier Laboratories

    Hospital Equipment Manufacturing Company (India)

    Hyperion Source

    Ig Dental

    Indica Chemical Industries

    Indo Webal Surgical

    Indo-German Surgical Corporation

    Indus Medicare

    Institute for OneWorld Health

    Intermarket India Private Limited


    IPCA Laboratories

    Iscon Surgicals

    Johnson & Johnson

    J.K. Ansell

    Jai Surgicals

    Jewel Consumer Care

    JJ Orthodontics

    Johari Digital Healthcare

    Johnson & Johnson

    Jubilant Organosys

    Jullundur Surgical Works

    Kanam Latex Industries

    Kanam Latex Industries

    Kdans Surgical


    Khosla Surgical Industries

    Kiran Medical Systems

    Labotech Microscopes India

    Larsen & Toubro

    Laxmi Dental Export

    Laxmi Electronics Moulds & Precision Engg

    Lifeline Systems

    LM First Aid Products

    Lonza Group

    Lupin Pharmaceuticals

    M/S Orthopaedic Appliance Company

    M/S Osi

    Madhu Instruments

    Marck Biosciences

    Marian Personal & Hygiene Care Products

    Matrix Clinical

    Mcm Overseas Agencies

    Medico Electrodes International

    Medicure Instruments

    Meditec Devices


    Medtech Products

    Merck & Co.

    MGRM Medicare

    Ministry of Science and Technology (India)

    Modern Orthodontics

    Mylan Pharmaceuticals

    Natco Pharma

    National Biotechnology Regulatory Authority (NBRA, India)

    National Health Service (NHS, UK)

    National Institutes of Health (NIH, US)

    National IP Strategy Formulation Office (NIPSO, China)

    Neuland Laboratories

    Nicholas Piramal

    Nipro Pharma Corporation

    Northeast General Pharmaceutical Factory


    Novella Clinical

    Novo Nordisk

    Orchid Chemicals and Pharmaceuticals





    Polymed Therapeutics


    Ranbaxy Laboratories

    Rhodia Group





    Shadong XINHUA Pharm

    Shandong New Time Pharmaceutical

    Shanghai Sunve Pharmaceutical

    Shasun Pharma Solutions

    Solvay Pharmaceuticals

    State Food and Drug Administration (SFDA, China)

    Sun Pharmaceutical Industries

    Suven Life Sciences


    Tata Consulting Services

    The National Biotechnology Regulatory Authority (NBRA)


    Verax Biomedical

    Vetter Pharma Fertigung


    World Trade Organisation (WTO)


    Zhejiang Jiuzhou Pharmaceutical

    Zhejiang Medicine

    Zhejiang NHU

    Zhejiang Supor Pharmaceuticals

    Zyday Cadila

    To order this report:Pharmaceutical Industry: Pharmaceutical Contract Manufacturing: Industry and Market Prospects 2010-2025

    Pharmaceutical Business News

    More Market Research Report

    Check our Company Profile, SWOT and Revenue Analysis!Contact Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626

    SOURCE Reportlinker
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Reportlinker Adds US Disposable Medical Supplies Market Report
    2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
    3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
    4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
    5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
    6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
    7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
    8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
    9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
    10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
    11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
    Post Your Comments:
    (Date:11/30/2015)... India , November 30, 2015 ... 2014, and is expected to grow at a CAGR of 7.6% ... was valued at USD 135.6 million in 2014, and is ... 2020. --> According to the new Market Research Report ... invasive, non-invasive), By End User (Hospitals, ambulatory care, others) - Analysis ...
    (Date:11/30/2015)... PUNE, India , November 30, 2015 ... new market research report "Dental Lasers Market by Product (Soft ... Treatment, Periodontitis), End User (Hospitals, Clinics), and Geography - Global ... USD 224.7 Million by 2020, at a CAGR of 5.2% ... , Browse 140 market data Tables and 62 Figures spread ...
    (Date:11/30/2015)... MOUNTLAKE TERRACE, Wash. and ST. ... Cross and Express Scripts (NASDAQ: ESRX ) today ... benefit agreement. The partnership, which began in 1999, will ... --> --> After evaluating pharmacy ... process, Premera concluded that Express Scripts continues to offer ...
    Breaking Medicine Technology:
    (Date:11/30/2015)... ... November 30, 2015 , ... The ... Dallas, TX, on January 29 and 30, 2016. The course welcomes dental professionals ... their practices, to learn how to better succeed in the modern dental marketplace. ...
    (Date:11/30/2015)... , ... November 30, 2015 , ... ... key disease-causing component of bacteria could be effective in fighting methicillin-resistant Staphylococcus aureus ... State University. , Their study showed that small molecule analogs that target the ...
    (Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... Dr. Seth ... three office locations, patients can visit Dr. Margulies to experience the best available orthodontic ... hold the title of "NJ Top Dentist"! , Orthodontics is the branch of dentistry ...
    (Date:11/30/2015)... , ... November 30, 2015 , ... ”Dying Words: The ... be released on December 1, 2015, to coincide with World AIDS Day. The multi-media ... journalist who covered the AIDS epidemic as he was dying of the disease. , ...
    (Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... Reports magazine, quoted Michael Hansen, Ph.D., a senior scientist at Consumer Reports as ... more so for a child’s exposure limits. , The original Nov 2015 CR ...
    Breaking Medicine News(10 mins):